Patents Assigned to Dyax Corp.
  • Multi-chain eukaryotic display vectors and uses thereof
    Patent number: 9556428
    Abstract: A eukaryotic expression vector capable of displaying a multi-chain polypeptide on the surface of a host cell is provided, such that the biological activity of the multi-chain polypeptide is exhibited at the surface of the host cell. Such a vector allows for the display of complex biologically active polypeptides, e.g., biologically active multi-chain polypeptides such as immunoglobulin Fab fragments. The present invention describes and enables the successful display of a multi-chain polypeptide on the surface of a eukaryotic host cell. Preferred vectors are described for expressing the chains of a multi-chain polypeptide in a host cell separately and independently (e.g., under separate vector control elements, and/or on separate expression vectors, thus forming a matched vector set).
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: January 31, 2017
    Assignee: Dyax Corp.
    Inventors: Simon E. Hufton, Hendricus Renerus Jacobus Mattheus Hoogenboom
  • PLASMA KALLIKREIN BINDING PROTEINS AND USES THEREOF IN TREATING HEREDITARY ANGIOEDEMA
    Publication number: 20170002094
    Abstract: Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.
    Type: Application
    Filed: January 21, 2015
    Publication date: January 5, 2017
    Applicant: Dyax Corp.
    Inventors: Daniel J. Sexton, Burt Adelman, Yung Chyung, Christopher TenHoor, Jon A. Kenniston, Ryan Faucette, Rayan larrobino, Joe Biedenkapp
  • PREVENTION AND REDUCTION OF BLOOD LOSS
    Publication number: 20160361395
    Abstract: Methods are described for preventing or reducing ischemia and/or systemic inflammatory response in a patient such as perioperative blood loss and/or systemic inflammatory response in a patient subjected to cardiothoracic surgery, e.g. coronary artery bypass grafting and other surgical procedures, especially when such procedures involve extra-corporeal circulation, such as cardiopulmonary bypass.
    Type: Application
    Filed: June 7, 2016
    Publication date: December 15, 2016
    Applicant: Dyax Corp.
    Inventors: Robert Charles Ladner, Arthur Charles Ley, Shirish Hirani, Anthony Williams
  • LIBRARIES OF GENETIC PACKAGES COMPRISING NOVEL HC CDR1, CDR2, AND CDR3 AND NOVEL LC CDR1, CDR2, AND CDR3 DESIGNS
    Publication number: 20160355571
    Abstract: Provided are compositions and methods for preparing and identifying antibodies having CDR3s that vary in sequence and in length from very short to very long which in certain embodiments may bind to a carbohydrate moiety or the active site of an enzyme. Libraries coding for antibodies with the CDR3s are also provided. The libraries can be provided by modifying a pre-existing nucleic acid library.
    Type: Application
    Filed: June 8, 2016
    Publication date: December 8, 2016
    Applicant: Dyax Corp.
    Inventor: Robert Charles Ladner
  • Prevention and reduction of blood loss
    Patent number: 9480733
    Abstract: Methods are described for preventing or reducing ischemia and/or systemic inflammatory response in a patient such as perioperative blood loss and/or systemic inflammatory response in a patient subjected to cardiothoracic surgery, e.g. coronary artery bypass grafting and other surgical procedures, especially when such procedures involve extra-corporeal circulation, such as cardiopulmonary bypass.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: November 1, 2016
    Assignee: Dyax Corp.
    Inventors: Robert C. Ladner, Arthur C. Ley, Shirish Hirani, Anthony Williams
  • KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
    Patent number: 9446155
    Abstract: The present invention provides polypeptides, peptide dimer, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a KD<1 ?M), and dimer and multimeric constructs comprising these polypeptides.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: September 20, 2016
    Assignees: Bracco Suisse SA, Dyax Corp.
    Inventors: Aaron K. Sato, Daniel J. Sexton, Daniel T. Dransfield, Robert Charles Ladner, Christophe Arbogast, Philippe Bussat, Hong Fan, Sudha Khurana, Karen E. Linder, Edmund R. Marinelli, Palaniappa Nanjappan, Adrian D. Nunn, Radhakrishna K. Pillai, Sibylle Pochon, Kondareddiar Ramalingam, Ajay Shrivastava, Bo Song, Rolf E. Swenson, Mathew A. Von Wronski, Feng Yan
  • ASSAYS FOR DETERMINING PLASMA KALLIKREIN SYSTEM BIOMARKERS
    Publication number: 20160252527
    Abstract: Methods and assays for determining the activation level of the plasma kallikrein (pKal) system and the uses thereof for assessing the activity of pKal modulators on the pKal system.
    Type: Application
    Filed: October 17, 2014
    Publication date: September 1, 2016
    Applicant: Dyax Corp.
    Inventors: Daniel J. Sexton, Ryan Faucette, Jon A. Kenniston, Gregory P. Conley, Andrew Nixon, Christopher TenHoor, Burt Adelman
  • DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DISEASES
    Publication number: 20160252533
    Abstract: Methods, kits and compositions for diagnosing and treating autoimmune diseases such as rheumatiodi arthritis, Crohn's disease, and ulcerative colitis.
    Type: Application
    Filed: October 17, 2014
    Publication date: September 1, 2016
    Applicant: Dyax Corp.
    Inventors: Daniel J. Sexton, Burt Adelman, Andrew Nixon
  • FC RECEPTOR BINDING PROTEINS
    Publication number: 20160222109
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: December 29, 2015
    Publication date: August 4, 2016
    Applicants: Dyax Corp., Biogen Hemophilia Inc.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James M. McGivney, Kevin A. McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
  • FC RECEPTOR BINDING PROTEINS
    Publication number: 20160222110
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: December 29, 2015
    Publication date: August 4, 2016
    Applicants: DYAX CORP., BIOGEN HEMOPHILIA INC.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James M. McGivney, Kevin A. McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
  • FC RECEPTOR BINDING PROTEINS
    Publication number: 20160222108
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: December 22, 2015
    Publication date: August 4, 2016
    Applicants: DYAX CORP., BIOGEN HEMOPHILIA INC.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James M. McGivney, Kevin A. McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
  • FC RECEPTOR BINDING PROTEINS
    Publication number: 20160222111
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: December 30, 2015
    Publication date: August 4, 2016
    Applicants: DYAX CORP., BIOGEN HEMOPHILIA INC.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James M. McGivney, Kevin A. McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
  • FC RECEPTOR BINDING PROTEINS
    Publication number: 20160222112
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: December 30, 2015
    Publication date: August 4, 2016
    Applicants: DYAX CORP., BIOGEN HEMOPHILIA INC.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James M. McGivney, Kevin A. McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
  • Libraries of genetic packages comprising novel HC CDR1, CDR2, and CDR3 and novel LC CDR1, CDR2, and CDR3 designs
    Patent number: 9388510
    Abstract: Provided are compositions and methods for preparing and identifying antibodies having CDR3s that vary in sequence and in length from very short to very long which in certain embodiments may bind to a carbohydrate moiety or the active site of an enzyme. Libraries coding for antibodies with the CDR3s are also provided. The libraries can be provided by modifying a pre-existing nucleic acid library.
    Type: Grant
    Filed: April 24, 2009
    Date of Patent: July 12, 2016
    Assignee: Dyax Corp.
    Inventor: Robert C. Ladner
  • FC RECEPTOR BINDING PROTEINS
    Publication number: 20160194397
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: December 31, 2015
    Publication date: July 7, 2016
    Applicants: DYAX CORP., BIOGEN HEMOPHILIA INC.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James M. McGivney, Kevin A. McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
  • Methods of constructing libraries of genetic packages that collectively display the members of a diverse family of peptides, polypeptides or proteins
    Patent number: 9382535
    Abstract: Methods useful in constructing libraries that collectively display members of diverse families of peptides, polypeptides or proteins and the libraries produced using those methods. Methods of screening those libraries and the peptides, polypeptides or proteins identified by such screens.
    Type: Grant
    Filed: February 28, 2006
    Date of Patent: July 5, 2016
    Assignee: Dyax Corp.
    Inventors: Robert C. Ladner, Edward H. Cohen, Horacio G. Nastri, Kristin L. Rookey, Rene Hoet
  • PLASMA KALLIKREIN BINDING PROTEINS
    Publication number: 20160102150
    Abstract: Plasma kallikrein binding proteins and methods of using such proteins are described.
    Type: Application
    Filed: December 15, 2015
    Publication date: April 14, 2016
    Applicant: Dyax Corp.
    Inventors: Daniel J. Sexton, Malini Viswanathan
  • Method of treating hereditary angioedema using plasma kallikrein binding antibodies
    Patent number: 9266964
    Abstract: Plasma kallikrein binding proteins and methods of using such proteins are described.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: February 23, 2016
    Assignee: Dyax Corp.
    Inventors: Daniel J. Sexton, Malini Viswanathan
  • Antibodies to FeRn and uses thereof
    Patent number: 9260520
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: February 16, 2016
    Assignees: DYAX CORP., BIOGEN HEMOPHILIA INC.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James McGivney, Kevin McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
  • MULTI-CHAIN EUKARYOTIC DISPLAY VECTORS AND USES THEREOF
    Publication number: 20160040157
    Abstract: A eukaryotic expression vector capable of displaying a multi-chain polypeptide on the surface of a host cell is provided, such that the biological activity of the multi-chain polypeptide is exhibited at the surface of the host cell. Such a vector allows for the display of complex biologically active polypeptides, e.g., biologically active multi-chain polypeptides such as immunoglobulin Fab fragments. The present invention describes and enables the successful display of a multi-chain polypeptide on the surface of a eukaryotic host cell. Preferred vectors are described for expressing the chains of a multi-chain polypeptide in a host cell separately and independently (e.g., under separate vector control elements, and/or on separate expression vectors, thus forming a matched vector set).
    Type: Application
    Filed: May 21, 2015
    Publication date: February 11, 2016
    Applicant: Dyax Corp.
    Inventors: Simon E. Hufton, Hendricus Renerus Jacobus Mattheus Hoogenboom